OV-3133(R2) cell line

Later relapse-derived HGSOC ascites cell line from the matched 3133 series for longitudinal treatment-evolution studies

Contributors

Inventor Institute
Anne-Marie Mes-Masson and Diane Provencher Centre Hospitalier de L’université de Montréal
SKU: 161783
Product description: OV-3133(R2) was derived from ascites from patient 3133 at a later relapse after chemotherapy. Together with TOV3133D, TOV-3133G and OV-3133(R), it provides a same-patient series spanning diagnosis and recurrent disease following several lines of treatment. This makes OV-3133(R2) particularly useful for comparing later treatment-associated disease states with earlier samples from the same patient, reducing confounding from inter-patient differences.
Alternate name: OV-3133(R2)
Gender: Female
CRISPR: No
Production details: Established from the cellular fraction of ascites collected by centrifugation. The cell lines were then maintained for 40 days in OSE with medium replaced weekly.
Additional notes: Patient 3133 received treatment of paclitaxel and carboplatin 1-3 months after sugery and confirmation of ovarian cancer diagnosis. A second sugery 6 months after the first detectede infiltration of the tumor in part of the abdomen. Patient was treated with dxorubicin and later carboplatin and gemcitabine after no significant changes of CA-125 levels were seen. Later imaging presented an increase in tumor mass whereby she was given etoposide orally for eight days.
Cellosaurus ID: CVCL_9T16
Receptors of note: No
Related tools: 161899 ; 161781 ; 161782
Cat. #: 161783
Cancer types: Ovarian cancer
Research Fields: Cancer
Organism: Human
Tissue: Derived from ascites of patient diagnosed with high-grade serous ovarian cancer at specific time points at diagnosis and relapse
Gender: Female
Morphology: No expression of the tumor suppressor p53 detected. Strong HER2 expression detected in protein extracts and observed in solid tissues by IHC. Spheroid formation: aggregate
Growth properties: Adherent
Primary citation: Létourneau et al. 2012. BMC Cancer. (12): 379. PMID: 22931248
Shipping conditions: Dry Ice
Growth medium: OSE medium contains 10% FBS, 0.5ug/mL amphotericin B and 50 ug/mL gentamicin
Atmosphere: Hypoxic condition of 5%O2 and 5%CO2
References:

Tomas et al. 2023. J Ovarian Res. 11

16(1):70. PMID: 37038202 Vias et al. 2023. Elife. 11

12:e83867. PMID: 37166279 Jubelin et al. 2022. Cell Biosci. 11

12(1):155. PMID: 36089610 Canals et al. 2022. Front Oncol. 4

12:856424. PMID: 35600398

Related Tools for Cell lines

Cat. # Tool Name
161781 TOV-3133G cell line Key Info View Tool
161782 OV-3133(R) cell line Key Info View Tool
161899 TOV3133D Key Info View Tool

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.